Novartis AG offers growth potential with a balanced drug portfolio, manageable debt, and shares priced below fair value.

We came across a bullish thesis on Novartis AG (NVS) on Stock Analysis Compilation’s Substack. In this article, we will ...

Novartis AG (NYSE:NVS) is one of the 11 best European stocks to invest in. On June 23, the company confirmed it had completed ...

Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial ...

We are excited to welcome the talented team at Regulus to Novartis as we continue to build on our pipeline in renal disease with high unmet medical need.” Farabursen is an investigational ...

Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. ("Regulus"). With the completion of the acquisition, shares of common stock ...

Novartis AG’s drug Cosentyx failed in a late-stage study of patients suffering from inflammation in their blood vessels, a ...

Kirkland & Ellis lawyers withdrew from representing Novartis AG in a lawsuit against Regeneron Inc. a week after the firm was ...

Novartis today announced that its previously announced tender offer (the "Offer") by Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis ...

The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 ...

Novartis said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), a condition characterised by inflammation of the arteries.